Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus

被引:37
作者
Jankowski, J
Moayyedi, P
机构
[1] Leicester Royal Infirm, Sch Med, Dept Genet, Leicester LE1 5WW, Leics, England
[2] Leicester Royal Infirm, Sch Med, Dept Mol Med, Leicester LE1 5WW, Leics, England
[3] Univ Hosp Trust, Royal Infirm, Leicester LE1 5WW, Leics, England
[4] Univ Leicester, Dept Genet, Ctr Digest Dis, Leicester LE1 7RH, Leics, England
[5] Univ Leicester, Dept Mol Med, Ctr Digest Dis, Leicester LE1 7RH, Leics, England
[6] Mc Master Univ, GI Unit, Hamilton, ON, Canada
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2004年 / 96卷 / 11期
关键词
D O I
10.1093/jnci/djh171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:885 / 887
页数:3
相关论文
共 4 条
[1]   Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis [J].
Corley, DA ;
Kerlikowske, K ;
Verma, R ;
Buffler, P .
GASTROENTEROLOGY, 2003, 124 (01) :47-56
[2]   Aspirin resistance - May be a cause of recurrent ischaemic vascular events in patients taking aspirin [J].
Hankey, GJ ;
Eikelboom, JW .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7438) :477-479
[3]   Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus [J].
Hur, C ;
Nishioka, NS ;
Gazelle, GS .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (04) :316-325
[4]   Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west [J].
Jankowski, JA ;
Provenzale, D ;
Moayyedi, P .
GASTROENTEROLOGY, 2002, 122 (02) :588-590